{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:03:43Z","timestamp":1788879823084,"version":"build-2803163510"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> This study compared the effect of indobufen with that of aspirin on platelet function in patients with stable coronary heart disease after percutaneous coronary intervention (PCI).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients with stable coronary heart disease who had undergone PCI and received dual antiplatelet therapy (aspirin 100\u00a0mg + clopidogrel 75\u00a0mg once daily) for at least 12\u00a0months were allocated to receive indobufen 100\u00a0mg twice daily + clopidogrel 75\u00a0mg once daily, clopidogrel 75\u00a0mg once daily alone, indobufen 100\u00a0mg twice daily alone, and aspirin 100\u00a0mg once daily alone for 1\u00a0month each in an open-label crossover manner. Platelet function was assessed by using the rates of arachidonic acid (AA)-induced platelet aggregation (AA-PAR) and adenosine diphosphate (ADP)-induced platelet aggregation (ADP-PAR) measured by light transmission aggregometry, the platelet reactivity index measured by vasodilator-stimulated phosphoprotein (PRI-VASP), and the plasma and urinary thromboxane B<jats:sub>2<\/jats:sub> (TXB<jats:sub>2<\/jats:sub>) concentrations recorded at baseline and during each treatment phase.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of 56 patients enrolled, 52 completed the study. The AA-PAR was lower in the indobufen alone group than in the aspirin alone group [5.21% (3.39, 7.98) vs. 5.27% (4.06, 6.60), <jats:italic>p<\/jats:italic> = 0.038], while biologically, a difference of 0.06% may represent no significant difference; there was no significant between-group difference in the plasma [531.16\u00a0pg\/ml (203.89, 1035.06) vs. 373.93\u00a0pg\/ml (194.04, 681.71), <jats:italic>p<\/jats:italic> = 0.251] or urinary [3951.97\u00a0pg\/ml (2006.95, 6077.01) vs. 3610.48\u00a0pg\/ml (1664.60, 6247.61), <jats:italic>p<\/jats:italic> = 0.717] TXB<jats:sub>2<\/jats:sub> concentration. When the aspirin + clopidogrel group and indobufen + clopidogrel group were compared, similar results were found for AA-PAR [3.97% (3.05, 5.12) vs. 3.83% (3.10, 5.59), <jats:italic>p<\/jats:italic> = 0.947] and both plasma [849.47\u00a0pg\/ml (335.96, 1634.54) vs. 455.41\u00a0pg\/ml (212.47, 1489.60), <jats:italic>p<\/jats:italic> = 0.629], and urinary [4122.97\u00a0pg\/ml (2044.96, 7459.86) vs. 3812.81\u00a0pg\/ml (1358.95, 6021.07), <jats:italic>p<\/jats:italic> = 0.165] TXB<jats:sub>2<\/jats:sub> concentrations. ADP-PAR was lower in the clopidogrel alone group than in the indobufen alone group (47.04% \u00b1 16.89 vs. 61.7% \u00b1 10.50, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), as was PRI-VASP (66.53% \u00b1 18.06 vs. 77.72% \u00b1 19.87, <jats:italic>p<\/jats:italic> = 0.002).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> These findings suggest that indobufen has antiplatelet effects similar to those of aspirin in patients with stable coronary heart disease after PCI, and may be an alternative for patients with aspirin intolerance after coronary stenting.<\/jats:p>","DOI":"10.3389\/fphar.2022.950719","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T06:53:45Z","timestamp":1660632825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: An open-label crossover study"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiu-Ping","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Yu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Fen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur. Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2014","journal-title":"Eur. Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.12037\/YXQY.2019.01-07","article-title":"Committee of experts on rational drug use of national health commission of the P.R.China.Rational medication guidelines for thrombolytic therapy for acute ST-segment elevation myocardial infarction (2nd edition)","volume":"11","author":"Author Anonymous","year":"2019","journal-title":"Chin. J. Front. Med. Sci. Version)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/09537104.2012.686072","article-title":"Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention","volume":"24","author":"Barill\u00e0","year":"2013","journal-title":"Platelets"},{"key":"B6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2165\/00002512-200118050-00007","article-title":"Indobufen: an updated review of its use in the management of atherothrombosis","volume":"18","author":"Bhana","year":"2001","journal-title":"Drugs Aging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e002896","DOI":"10.1161\/CIRCINTERVENTIONS.115.002896","article-title":"Efficacy and safety of available protocols for aspirin hypersensitivity for patients undergoing percutaneous coronary intervention: a survey and systematic review","volume":"9","author":"Bianco","year":"2016","journal-title":"Circ. Cardiovasc. Interv."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/j.1538-7836.2012.04875.x","article-title":"Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel","volume":"10","author":"Bonello","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"B9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/01.cir.96.4.1109","article-title":"Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina","volume":"96","author":"Cipollone","year":"1997","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"Cox","year":"2006","journal-title":"Stroke"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1055\/s-0038-1650306","article-title":"A prostacyclin-sparing effect of indobufen vs. aspirin","volume":"75","author":"De Caterina","year":"1996","journal-title":"Thromb. Haemost."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e000651","DOI":"10.1136\/openhrt-2017-000651","article-title":"Dual antiplatelet therapy for secondary prevention of coronary artery disease","volume":"4","author":"Degrauwe","year":"2017","journal-title":"Open Heart"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1161\/01.cir.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2036.2006.02759.x","article-title":"Upper gastrointestinal bleeding associated with antiplatelet drugs","volume":"23","author":"Ib\u00e1\u00f1ez","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ijcard.2011.08.080","article-title":"Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: a proposed alternative regimen","volume":"165","author":"Latib","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3109\/09537104.2015.1042853","article-title":"Comparison of aspirin and indobufen in healthy volunteers","volume":"27","author":"Lee","year":"2016","journal-title":"Platelets"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1056\/NEJM197405232902102","article-title":"Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. a report from the boston collaborative drug surveillance program, boston university medical center","volume":"290","author":"Levy","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s11481-020-09978-9","article-title":"Pretreatment of indobufen and aspirin and their combinations with clopidogrel or ticagrelor alleviates inflammasome mediated pyroptosis via inhibiting NF-\u03baB\/NLRP3 pathway in ischemic stroke","volume":"16","author":"Li","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00045391-200403000-00004","article-title":"Endoscopic evaluation of the effects of indobufen and aspirin in healthy volunteers","volume":"11","author":"Marzo","year":"2004","journal-title":"Am. J. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/gut.20.1.75","article-title":"Gastrointestinal cytoprotection by prostaglandins","volume":"20","author":"Miller","year":"1979","journal-title":"Gut"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1161\/01.str.28.5.1015","article-title":"Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators","volume":"28","author":"Morocutti","year":"1997","journal-title":"Stroke"},{"key":"B27","first-page":"217","article-title":"Pharmacology of thromboxane A2, prostacyclin and other eicosanoids in the cardiovascular system","volume":"46","author":"M\u00fcller","year":"1991","journal-title":"Therapie"},{"key":"B28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1111\/j.1538-7836.2010.03997.x","article-title":"The role of weight and enteric coating on aspirin response in cardiovascular patients","volume":"8","author":"Peace","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1160\/TH16-05-0377","article-title":"Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y(12) receptor inhibitors","volume":"116","author":"Rollini","year":"2016","journal-title":"Thromb. Haemost."},{"key":"B31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.iac.2004.03.001","article-title":"Aspirin and NSAID sensitivity","volume":"24","author":"Stevenson","year":"2004","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"B32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.4103\/0366-6999.152611","article-title":"Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel","volume":"128","author":"Tang","year":"2015","journal-title":"Chin. Med. J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2165\/00003495-199244030-00009","article-title":"Indobufen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease","volume":"44","author":"Wiseman","year":"1992","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00228-021-03177-y","article-title":"Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis","volume":"77","author":"Yang","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.950719\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T06:53:51Z","timestamp":1660632831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.950719\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":35,"alternative-id":["10.3389\/fphar.2022.950719"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.950719","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"article-number":"950719"}}